Skip to content

ANI PHARMACEUTICALS INC

ANIP

CIK 0001023024

← back to feed
Revenue (TTM)
$873.77M
+43.8% YoY Q1 Mar 2026
Net Income (TTM)
$80.34M
+522.9% YoY Q1 Mar 2026
EPS Diluted (TTM)
$3.46
+419.2% YoY Q1 Mar 2026
Gross Margin
90.5%
Q1 Mar 2026
Operating Margin
13.2%
Q1 Mar 2026
Net Margin
9.2%
Q1 Mar 2026
Free Cash Flow (TTM)
$117.58M
Q1 Mar 2026
Cash
$311.18M
Q1 Mar 2026
Total Debt
$305.29M
Q1 Mar 2026
Shares Outstanding
24.42M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings